Close Menu

HTG Molecular

The two companies have signed a new master collaboration agreement under which HTG will  develop custom assays for use in earlier stages of Merck's drug development process.

The Federal Trade Commission said today that Becton Dickinson and CR Bard have agreed to divest two medical device product lines to settle its complaint that the proposed $24-billion acquisition would negatively impact competition.

Third quarter growth was driven by a sharp increase in revenues from HTG Molecular's pharmaceutical partners.

Alere this week informed the New York Stock Exchange in writing of its intention to voluntarily delist its Series B convertible perpetual preferred stock from the exchange.

While the company reported an increase in revenues from biopharma partners, this gain was more than offset by lower consumable sales.

The firm's market value fell below the minimum $35 million level to remain listed on the Nasdaq. HTG has until Jan 29, 2018 to regain compliance. 

The companies will use HTG EdgeSeq technology to develop NGS-based gene expression profiling assays to support a pharma company's therapeutic development.

HTG Molecular Diagnostics has amended and restated an IVD test development and component supply agreement with Illumina to extend the agreement term and increase the number of in vitro diagnostic test kits that may be developed using Illumina’s sequencing technology.

Pages